Voloridge Investment Management
PRLD icon

Voloridge Investment Management’s Prelude Therapeutics PRLD Stock Holding History

Voloridge Investment Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,743
Closed -$81K – 1594
2022
Q1 		$81K Sell
11,743
-27,271
-70% -$249K ﹤0.01% 1317
2021
Q4 		$486K Buy
+39,014
New +$635K ﹤0.01% 1413
2021
Q3 		– Sell
-15,319
Closed -$439K – 1822
2021
Q2 		$439K Buy
+15,319
New +$545K ﹤0.01% 1462

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Voloridge Investment Management's PRLD Position: Q2 2022 in Review

Voloridge Investment Management sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 11,743 shares — an estimated $81K sold.

Voloridge Investment Management first reported a position in PRLD in Q2 2021 and held it in 3 quarters. The position peaked at $486K in Q4 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

  • Voloridge Investment Management reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 11,743 Prelude Therapeutics shares in Q2 2022, an estimated $81K.
  • Voloridge Investment Management first reported a position in Prelude Therapeutics in Q2 2021 and held it in 3 quarters.
  • Voloridge Investment Management's Prelude Therapeutics position peaked at $486K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on Voloridge Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.